What’s Driving Immuron’s (ASX:IMC; NASDAQ:IMRN) Pipeline Progress and FY26 Outlook?

Immuron is heading into the second half of FY26 with real momentum. HY26 revenue hit A$4.2 million (up 5% on the prior period), cash reserves have grown to A$10 million, and net assets have increased to A$13.07 million. Beyond the financials, the company secured FDA approval for an IND application to advance IMM-529 into Phase 2 trials for recurrent C. difficile infection, landed a new US Department of Defense award targeting Campylobacter and Shigella, and launched ProIBS in Australia. Management is guiding for net sales, net profit, and EBITDX to all exceed the prior corresponding period in 2H FY26.

Read the Full Article Here